Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price TargetTip Ranks·2 hours agoGILD+180.00%GIS
Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading DayMarketWatch Automated·3 hours agoGILD+180.00%GIS
Key facts: Kymera (KYMR) Q2 $65M; $1.5B cash; KT-621 data end-2026TradingView·1 day ago, 02:15 AMKYMR+104.00%SNY+133.00%
Gilead Sciences declares Q3 2026 distribution of R$ 1.42 per unit for BRGILDBDR 000PUBT·2 days ago, 02:36 PMGILD+180.00%GIS
Kymera Q2 2026 Earnings: Milestone Revenue Narrows Net LossTradingKey·2 days ago, 06:45 AMKYMR+104.00%GILD+180.00%
Dow Jones Top Company Headlines at 1 AM ET: SpaceX Says Spending Spree Is Supercharging AI Revenues | The ...MorningStar·2 days ago, 12:27 AMPINS+150.00%LCID+86.00%
Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury dropbusinessinsider·2 days ago, 12:16 AMGILD+180.00%GIS
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results | GILD Stock NewsStockTitan·Aug 4 at 07:01 AMGILD+180.00%GIS
